Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19330978 | 1.00 | TRIM24 (0.36) | TRIM24TYRTRIM33MAPTALDH1A1 | |
| SCHEMBL19343270 | 0.89 | SCD (0.38) | TRIM24TYRTRIM33MAPTALDH1A1 | |
| SCHEMBL21490371 | 0.85 | CYP1A1 (0.42) | TRIM24TYRTRIM33MAPTALDH1A1 | |
| SCHEMBL21490370 | 0.85 | CYP1A1 (0.42) | TRIM24TYRTRIM33MAPTALDH1A1 | |
| SCHEMBL28700331 | 0.85 | CYP1A1 (0.42) | TRIM24TYRTRIM33MAPTALDH1A1 | |
| SCHEMBL29063150 | 0.80 | CA1 (0.37) | MAPTALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL20536245 | 0.79 | SMN1; SMN2 (0.37) | ALDH1A1LMNAHPGDNPC1RAB9A | |
| SCHEMBL29015479 | 0.79 | SMN1; SMN2 (0.37) | ALDH1A1LMNAHPGDNPC1RAB9A | |
| SCHEMBL20536246 | 0.79 | SMN1; SMN2 (0.37) | ALDH1A1LMNAHPGDNPC1RAB9A | |
| SCHEMBL19331152 | 0.78 | POLB (0.34) | MAPTALDH1A1KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3884939-B1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11634412-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230009122-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| EP-3884939-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | Raze Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3426243-B1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-10954220-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20190071431-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2019-03-07 | — | — | US | disclosed |
| EP-3426243-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | Raze Therapeutics Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017156165-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634412-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | PHGDH, G6PD, PGD | TRIM24 3136/4885TYR 2383/4885TRIM33 3019/4885 |
| US-20230009122-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | TRIM24 3136/4885TYR 2383/4885TRIM33 3019/4885 |
| US-20190071431-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | TRIM24 3136/4885TYR 2383/4885TRIM33 3019/4885 |
| US-10954220-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | PHGDH, G6PD, PGD | TRIM24 3136/4885TYR 2383/4885TRIM33 3019/4885 |
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | TRIM24 3136/4885TYR 2383/4885TRIM33 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.